Abstract
Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response. The decrease in the production of the amyloidogenic light chains is a required condition to obtain the organ response, which is commonly delayed. Meanwhile, supportive treatment is aimed to maintain quality of life of these patients and preserve their involved organs’ function. From simple measures, such as salt restriction or compressive stockings, to very complex interventions, such as heart transplantation in very selected patients with isolated severe cardiac involvement, this supportive care is essential and has to be necessarily included in the multidisciplinary management of this disease.
References
1.
Merlini
G
, Bellotti
V
. Molecular mechanisms of amyloidosis
. N Engl J Med
. 2003
Aug
;349
(6
):583
–96
.
[PubMed]
0028-47932.
Sikkink
LA
, Ramirez-Alvarado
M
. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture
. Cell Death Dis
. 2010
Nov
;1
(11
):e98
.
[PubMed]
2041-48893.
Comenzo
RL
, Wally
J
, Kica
G
, Murray
J
, Ericsson
T
, Skinner
M
, et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation
. Br J Haematol
. 1999
Sep
;106
(3
):744
–51
.
[PubMed]
0007-10484.
Prokaeva
T
, Spencer
B
, Kaut
M
, Ozonoff
A
, Doros
G
, Connors
LH
, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival
. Arthritis Rheum
. 2007
Nov
;56
(11
):3858
–68
.
[PubMed]
0004-35915.
Perfetti
V
, Palladini
G
, Casarini
S
, Navazza
V
, Rognoni
P
, Obici
L
, et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44
. Blood
. 2012
Jan
;119
(1
):144
–50
.
[PubMed]
0006-49716.
Milani
P
, Merlini
G.
Monoclonal IgM-related AL amyloidosis.
Best Pract Res Clin Haematol. 2016
;29(2):241-248. 18. 7.
Sidiqi
MH
, Aljama
MA
, Muchtar
E
, Buadi
FK
, Warsame
R
, Lacy
MQ
, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation
. Blood Adv
. 2018
Apr
;2
(7
):769
–76
.
[PubMed]
2473-95298.
Dispenzieri
A
, Buadi
F
, Kumar
SK
, Reeder
CB
, Sher
T
, Lacy
MQ
, et al. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
. Mayo Clin Proc
. 2015
Aug
;90
(8
):1054
–81
.
[PubMed]
0025-61969.
Kumar
S
, Dispenzieri
A
, Lacy
MQ
, Hayman
SR
, Buadi
FK
, Colby
C
, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
. J Clin Oncol
. 2012
Mar
;30
(9
):989
–95
.
[PubMed]
0732-183X10.
Bhutani
D
, Leng
S
, Lentzsch
S
. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis
. Clin Lymphoma Myeloma Leuk
. 2019
Sep
;19
(9
):555
–9
.
[PubMed]
2152-265011.
Kyle
RA
, Gertz
MA
. Primary systemic amyloidosis: clinical and laboratory features in 474 cases
. Semin Hematol
. 1995
Jan
;32
(1
):45
–59
.
[PubMed]
0037-196312.
Gentile
G
, Remuzzi
G
, Ruggenenti
P
. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny
. Nephron
. 2015
;129
(1
):39
–41
.
[PubMed]
0028-276613.
Lee
T
, Biddle
AK
, Lionaki
S
, Derebail
VK
, Barbour
SJ
, Tannous
S
, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy
. Kidney Int
. 2014
Jun
;85
(6
):1412
–20
.
[PubMed]
0085-253814.
Pinney
JH
, Lachmann
HJ
, Bansi
L
, Wechalekar
AD
, Gilbertson
JA
, Rowczenio
D
, et al. Outcome in renal Al amyloidosis after chemotherapy
. J Clin Oncol
. 2011
Feb
;29
(6
):674
–81
.
[PubMed]
0732-183X15.
Gertz
MA
, Kyle
RA
, O’Fallon
WM
. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients
. Arch Intern Med
. 1992
Nov
;152
(11
):2245
–50
.
[PubMed]
0003-992616.
Palladini
G
, Hegenbart
U
, Milani
P
, Kimmich
C
, Foli
A
, Ho
AD
, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
. Blood
. 2014
Oct
;124
(15
):2325
–32
.
[PubMed]
0006-497117.
Moroni
G
, Banfi
G
, Montoli
A
, Bucci
A
, Bertani
T
, Ravelli
M
, et al. Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy
. Clin Nephrol
. 1992
Aug
;38
(2
):81
–5
.
[PubMed]
0301-043018.
Sattianayagam
PT
, Gibbs
SD
, Pinney
JH
, Wechalekar
AD
, Lachmann
HJ
, Whelan
CJ
, et al. Solid organ transplantation in AL amyloidosis
. Am J Transplant
. 2010
Sep
;10
(9
):2124
–31
.
[PubMed]
1600-613519.
Herrmann
SM
, Gertz
MA
, Stegall
MD
, Dispenzieri
A
, Cosio
FC
, Kumar
S
, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation
. Nephrol Dial Transplant
. 2011
Jun
;26
(6
):2032
–6
.
[PubMed]
0931-050920.
Angel-Korman
A
, Stern
L
, Sarosiek
S
, Sloan
JM
, Doros
G
, Sanchorawala
V
, et al. Long-term outcome of kidney transplantation in AL amyloidosis
. Kidney Int
. 2019
Feb
;95
(2
):405
–11
.
[PubMed]
0085-253821.
Sathick
IJ
, Rosenbaum
CA
, Gutgarts
V
, Landau
H
. Kidney transplantation in AL Amyloidosis: is it time to maximize access?
Br J Haematol
. 2020
Feb
;188
(3
):e1
–4
.
[PubMed]
0007-104822.
Aljama
MA
, Sidiqi
MH
, Dispenzieri
A
, Gertz
MA
, Lacy
MQ
, Buadi
FK
, et al. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis
. Blood Adv
. 2019
Apr
;3
(8
):1226
–9
.
[PubMed]
2473-952923.
Dispenzieri
A
, Gertz
MA
, Kyle
RA
, Lacy
MQ
, Burritt
MF
, Therneau
TM
, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
. J Clin Oncol
. 2004
Sep
;22
(18
):3751
–7
.
[PubMed]
0732-183X24.
Gertz
MA
, Lacy
MQ
, Dispenzieri
A
. Therapy for immunoglobulin light chain amyloidosis: the new and the old
. Blood Rev
. 2004
Mar
;18
(1
):17
–37
.
[PubMed]
0268-960X25.
Dispenzieri
A
, Merlini
G
. Immunoglobulin light chain systemic amyloidosis
. Cancer Treat Res
. 2016
;169
:273
–318
.
[PubMed]
0927-304226.
Kapoor
P
, Thenappan
T
, Singh
E
, Kumar
S
, Greipp
PR
. Cardiac amyloidosis: a practical approach to diagnosis and management
. Am J Med
. 2011
Nov
;124
(11
):1006
–15
.
[PubMed]
0002-934327.
Gertz
MA
, Falk
RH
, Skinner
M
, Cohen
AS
, Kyle
RA
. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents
. Am J Cardiol
. 1985
Jun
;55
(13 Pt 1
):1645
.
[PubMed]
0002-914928.
Palladini
G
, Malamani
G
, Cò
F
, Pistorio
A
, Recusani
F
, Anesi
E
, et al. Holter monitoring in AL amyloidosis: prognostic implications
. Pacing Clin Electrophysiol
. 2001
Aug
;24
(8 Pt 1
):1228
–33
.
[PubMed]
0147-838929.
Kristen
AV
, Dengler
TJ
, Hegenbart
U
, Schonland
SO
, Goldschmidt
H
, Sack
FU
, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death
. Heart Rhythm
. 2008
Feb
;5
(2
):235
–40
.
[PubMed]
1547-527130.
Sayed
RH
, Rogers
D
, Khan
F
, Wechalekar
AD
, Lachmann
HJ
, Fontana
M
, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis
. Eur Heart J
. 2015
May
;36
(18
):1098
–105
.
[PubMed]
0195-668X31.
Rubinow
A
, Skinner
M
, Cohen
AS
. Digoxin sensitivity in amyloid cardiomyopathy
. Circulation
. 1981
Jun
;63
(6
):1285
–8
.
[PubMed]
0009-732232.
Weber
N
, Mollee
P
, Augustson
B
, Brown
R
, Catley
L
, Gibson
J
, et al. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
. Intern Med J
. 2015
Apr
;45
(4
):371
–82
.
[PubMed]
1444-090333.
Barbhaiya
CR
, Kumar
S
, Baldinger
SH
, Michaud
GF
, Stevenson
WG
, Falk
R
, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy
. Heart Rhythm
. 2016
Feb
;13
(2
):383
–90
.
[PubMed]
1547-527134.
Dhoble
A
, Khasnis
A
, Olomu
A
, Thakur
R
. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review
. Clin Cardiol
. 2009
Aug
;32
(8
):E63
–5
.
[PubMed]
0160-928935.
Yaoita
H
, Iwai-Takano
M
, Ogawa
K
, Suzuki
H
, Akutsu
K
, Noji
H
, et al. Attenuation of diastolic heart failure and life-threatening ventricular tachyarrhythmia after peripheral blood stem cell transplantation combined with cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis
. Circ J
. 2008
Feb
;72
(2
):331
–4
.
[PubMed]
1346-984336.
Dubrey
S
, Pollak
A
, Skinner
M
, Falk
RH
. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation
. Br Heart J
. 1995
Nov
;74
(5
):541
–4
.
[PubMed]
0007-076937.
Feng
D
, Syed
IS
, Martinez
M
, Oh
JK
, Jaffe
AS
, Grogan
M
, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis
. Circulation
. 2009
May
;119
(18
):2490
–7
.
[PubMed]
0009-732238.
Feng
D
, Edwards
WD
, Oh
JK
, Chandrasekaran
K
, Grogan
M
, Martinez
MW
, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis
. Circulation
. 2007
Nov
;116
(21
):2420
–6
.
[PubMed]
0009-732239.
Falk
RH
, Alexander
KM
, Liao
R
, Dorbala
S
. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy
. J Am Coll Cardiol
. 2016
Sep
;68
(12
):1323
–41
.
[PubMed]
0735-109740.
Grogan
M
, Gertz
M
, McCurdy
A
, Roeker
L
, Kyle
R
, Kushwaha
S
, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience
. World J Transplant
. 2016
Jun
;6
(2
):380
–8
.
[PubMed]
2220-323041.
Dubrey
SW
, Burke
MM
, Hawkins
PN
, Banner
NR
. Cardiac transplantation for amyloid heart disease: the United Kingdom experience
. J Heart Lung Transplant
. 2004
Oct
;23
(10
):1142
–53
.
[PubMed]
1053-249842.
Kristen
AV
, Sack
FU
, Schonland
SO
, Hegenbart
U
, Helmke
BM
, Koch
A
, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis
. Eur J Heart Fail
. 2009
Oct
;11
(10
):1014
–20
.
[PubMed]
1388-984243.
Dey
BR
, Chung
SS
, Spitzer
TR
, Zheng
H
, Macgillivray
TE
, Seldin
DC
, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure
. Transplantation
. 2010
Oct
;90
(8
):905
–11
.
[PubMed]
0041-133744.
Gray Gilstrap
L
, Niehaus
E
, Malhotra
R
, Ton
VK
, Watts
J
, Seldin
DC
, et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis
. J Heart Lung Transplant
. 2014
Feb
;33
(2
):149
–56
.
[PubMed]
1053-249845.
Mehra
MR
, Canter
CE
, Hannan
MM
, Semigran
MJ
, Uber
PA
, Baran
DA
, et al.; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils
. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update
. J Heart Lung Transplant
. 2016
Jan
;35
(1
):1
–23
.
[PubMed]
1053-249846.
Qualls
DA
, Lewis
GD
, Sanchorawala
V
, Staron
A
. Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature
. Am J Transplant
. 2019
Nov
;19
(11
):3185
–90
.
[PubMed]
1600-613547.
Merlini
G
, Dispenzieri
A
, Sanchorawala
V
, Schönland
SO
, Palladini
G
, Hawkins
PN
, et al. Systemic immunoglobulin light chain amyloidosis
. Nat Rev Dis Primers
. 2018
Oct
;4
(1
):38
.
[PubMed]
2056-676X48.
Freeman
R
. Clinical practice. Neurogenic orthostatic hypotension
. N Engl J Med
. 2008
Feb
;358
(6
):615
–24
.
[PubMed]
0028-479349.
Yam
LT
, Oropilla
SB
. Octreotide for diarrhea in amyloidosis
. Ann Intern Med
. 1991
Oct
;115
(7
):577
.
[PubMed]
0003-481950.
Wixner
J
, Suhr
OB
, Anan
I
. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years
. Expert Rev Gastroenterol Hepatol
. 2018
Jan
;12
(1
):73
–81
.
[PubMed]
1747-412451.
Rives
S
, Pera
M
, Rosiñol
L
, Vidal
O
, Miquel
R
, Solé
M
, et al. Primary systemic amyloidosis presenting as a colonic stricture: successful treatment with left hemicolectomy followed by autologous hematopoietic stem-cell transplantation: report of a case
. Dis Colon Rectum
. 2002
Sep
;45
(9
):1263
–6
.
[PubMed]
0012-370652.
Park
MA
, Mueller
PS
, Kyle
RA
, Larson
DR
, Plevak
MF
, Gertz
MA
. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients
. Medicine (Baltimore)
. 2003
Sep
;82
(5
):291
–8
.
[PubMed]
0025-797453.
Oran
B
, Wright
DG
, Seldin
DC
, McAneny
D
, Skinner
M
, Sanchorawala
V
. Spontaneous rupture of the spleen in AL amyloidosis
. Am J Hematol
. 2003
Oct
;74
(2
):131
–5
.
[PubMed]
0361-860954.
Berk
JL
, O’Regan
A
, Skinner
M
. Pulmonary and tracheobronchial amyloidosis
. Semin Respir Crit Care Med
. 2002
Apr
;23
(2
):155
–65
.
[PubMed]
1069-342455.
Baumgart
JV
, Stuhlmann-Laeisz
C
, Hegenbart
U
, Nattenmüller
J
, Schönland
S
, Krüger
S
, et al. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management
. Virchows Arch
. 2018
Nov
;473
(5
):627
–37
.
[PubMed]
0945-631756.
Fiorelli
A
, Accardo
M
, Galluccio
G
, Santini
M
. Tracheobronchial amyloidosis treated by endobronchial laser resection and self expanding Y stent
. Arch Bronconeumol
. 2013
Jul
;49
(7
):303
–5
.
[PubMed]
0300-289657.
Kurrus
JA
, Hayes
JK
, Hoidal
JR
, Menendez
MM
, Elstad
MR
. Radiation therapy for tracheobronchial amyloidosis
. Chest
. 1998
Nov
;114
(5
):1489
–92
.
[PubMed]
0012-369258.
Vivino
FB
. Sjogren’s syndrome: clinical aspects
. Clin Immunol
. 2017
Sep
;182
:48
–54
.
[PubMed]
1521-661659.
Thibault
I
, Vallières
I
. Macroglossia due to Systemic Amyloidosis: Is There a Role for Radiotherapy?
Case Rep Oncol
. 2011
May
;4
(2
):392
–9
.
[PubMed]
1662-657560.
Pau
M
, Reinbacher
KE
, Feichtinger
M
, Kärcher
H
. Surgical treatment of macroglossia caused by systemic primary amyloidosis
. Int J Oral Maxillofac Surg
. 2013
Feb
;42
(2
):294
–7
.
[PubMed]
0901-502761.
Gadiwalla
Y
, Burnham
R
, Warfield
A
, Praveen
P
. Surgical management of macroglossia secondary to amyloidosis
. BMJ Case Rep
. 2016
Apr
;2016
:1136
.
[PubMed]
1757-790X62.
Choufani
EB
, Sanchorawala
V
, Ernst
T
, Quillen
K
, Skinner
M
, Wright
DG
, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy
. Blood
. 2001
Mar
;97
(6
):1885
–7
.
[PubMed]
0006-497163.
Thompson
CA
, Kyle
R
, Gertz
M
, Heit
J
, Pruthi
R
, Pardanani
A
. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients
. Am J Hematol
. 2010
Mar
;85
(3
):171
–3
.
[PubMed]
0361-860964.
Elsaman
AM
, Radwan
AR
, Akmatov
MK
, Della Beffa
C
, Walker
A
, Mayer
CT
, et al. Amyloid arthropathy associated with multiple myeloma: a systematic analysis of 101 reported cases
. Semin Arthritis Rheum
. 2013
Dec
;43
(3
):405
–12
.
[PubMed]
0049-0172© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
